SG11202107488PA - Methods of treating breast cancer with tucatinib - Google Patents

Methods of treating breast cancer with tucatinib

Info

Publication number
SG11202107488PA
SG11202107488PA SG11202107488PA SG11202107488PA SG11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA
Authority
SG
Singapore
Prior art keywords
subject
months
protein
tucatinib
cytochrome
Prior art date
Application number
SG11202107488PA
Other languages
English (en)
Inventor
Luke Walker
Christopher Endres
Anthony Lee
Hao Sun
Ariel Topletz-Erickson
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of SG11202107488PA publication Critical patent/SG11202107488PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202107488PA 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib SG11202107488PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
PCT/US2020/014953 WO2020159822A1 (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Publications (1)

Publication Number Publication Date
SG11202107488PA true SG11202107488PA (en) 2021-08-30

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107488PA SG11202107488PA (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Country Status (13)

Country Link
US (1) US20220193076A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917533A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523045A (cg-RX-API-DMAC7.html)
KR (1) KR20210119498A (cg-RX-API-DMAC7.html)
CN (1) CN113613656A (cg-RX-API-DMAC7.html)
AR (1) AR119681A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020215551A1 (cg-RX-API-DMAC7.html)
CA (1) CA3126279A1 (cg-RX-API-DMAC7.html)
IL (1) IL284850A (cg-RX-API-DMAC7.html)
MX (1) MX2021008834A (cg-RX-API-DMAC7.html)
SG (1) SG11202107488PA (cg-RX-API-DMAC7.html)
TW (1) TW202042820A (cg-RX-API-DMAC7.html)
WO (1) WO2020159822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
IL301405A (en) * 2020-09-28 2023-05-01 Seagen Inc Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
CN117243959B (zh) * 2022-10-13 2026-03-06 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers

Also Published As

Publication number Publication date
EP3917533A1 (en) 2021-12-08
CN113613656A (zh) 2021-11-05
JP2022523045A (ja) 2022-04-21
US20220193076A1 (en) 2022-06-23
CA3126279A1 (en) 2020-08-06
TW202042820A (zh) 2020-12-01
KR20210119498A (ko) 2021-10-05
AR119681A1 (es) 2022-01-05
IL284850A (en) 2021-08-31
MX2021008834A (es) 2021-09-28
WO2020159822A1 (en) 2020-08-06
AU2020215551A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US12048698B2 (en) Treatment of HER2 positive cancers
US20220193076A1 (en) Methods of treating breast cancer with tucatinib
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
US20230039711A1 (en) Ahr inhibitors and uses thereof
JP2022553041A (ja) Her2陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
US20260053802A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2008501006A (ja) Srcキナーゼ阻害剤AZD0530、および、抗エストロゲン剤またはEGFR−TK−阻害剤を含む組み合わせ製品
EP2407786A1 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
CN117460514A (zh) 用于治疗idh抑制剂耐药的对象的方法
US20250049807A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
HK40003387A (en) Therapeutic compositions for treating pancreatic cancer
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований